If you liked this article you might like

SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss
Biogen Should Either a Buyer or a Seller Be
Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results
SAGE Shares Surge After Postpartum Depression Drug Shows Promise